Fulyzaq Approved for HIV Patients
This week, the US Food and Drug Administration announced approval for Fulyzaq , a drug designed to treat symptoms of diarrhea in HIV/AIDS patients. It's the first drug for this purpose to win FDA approval.
FDA Approves First Anti-Diarrheal Drug for HIV/AIDS Patients
The US Food and Drug Administration today approved Fulyzaq ( crofelemer ) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection. Diarrhea is experienced by many HIV/AIDS patients and is a common reason why patients discontinue or switch their antiretroviral therapies. Fulyzaq is intended to be used in HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite. Patients take Fulyzaq two times a day to manage watery diarrhea due to the secretion of electrolytes ...
Flossing Your Cancer Risks Away
You've been told to floss at least once a day to keep your gums healthy. Keeping gum disease and inflammation out of your mouth could do more than improve your smile.
Get Vaccinated, Stop the Spread of Hep B
There are a great deal of complications associated with diabetes. In order to prevent these complications, patients have to take special care of themselves, whether that means eating healthier or getting vaccinated.
Banning HIV Organ Donation
Researchers from Johns Hopkins believe that a law banning HIV patients from donating their organs to living HIV-positive patients is outdated. If the ban were reversed, hundreds of HIV-positive patients who need an organ could get their transplant within months instead of years.
Help is Here, but You Aren't Eligible
Lack of health insurance coverage may affect hepatitis C patients' access to current antiviral treatments, according to a new study.
When Hepatitis A Turns Fatal
A study from South Korea has found a link between the Hepatitis A virus and patients with pre-existing chronic liver disease and identified the age group most at risk.
The Critical Interim
Scientists have created an antibody to remove the Hepatitis C virus from the bloodstream during liver transplant surgery in an effort to prevent re-infection of the organ, a problem that occurs in most cases.